UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

Study presents new persistence analysis of FINTEPLA, evaluating the efficacy and tolerability of FINTEPLA over a span of 12 months1 Real-world data looks into the need for resources to support caregivers – both parents and siblings – of people living with developmental and epileptic encephalopathies such as Dravet and Lennox-Gastaut syndromes in the transition from […]

Related Keywords

Florida ,United States ,Brussels ,Bruxelles Capitale ,Belgium ,Smyrna ,Izmir ,Turkey ,Orlando ,American ,Becky Malone ,Lauried Bailey ,Tom Stanton ,Brad Chapman ,Antje Witte ,Rare Epilepsy Parents ,A Survey Of Rare Epilepsy Parents ,Program See Boxed Warning ,Guideline Development ,Twitter ,Group Of Companies ,Epilepsy Foundation ,Corporate Communications ,Child Neurology Foundation ,Bull World Health Organ ,Ucb Inc ,American Epilepsy Society Annual Meeting ,Danny Did Foundation ,American Epilepsy Society ,Annual Meeting ,Rare Syndromes ,Month Persistence Analysis ,Dravet Syndrome ,Komodo Healthcare ,Adult Siblings ,Prepare Families Living ,Long Term Adult Care Planning ,Their Loved ,Gap Between Neurologists ,Systematic Literature Review ,Heart Disease ,Pulmonary Arterial Hypertension ,Boxed Warning ,Mitigation Strategy ,Decreased Weight ,Antiepileptic Drugs ,Blood Pressure ,Prescribing Information ,Medication Guide ,Important Safety Information ,Euronext Brussels ,Epileptic Encephalopathy ,Accessed November ,Epilepsy Behav ,Implementation Subcommittee ,American Academy ,American Epilepsy ,World Health ,Who Can Get ,